Novato-based Raptor Pharmaceutical Corp has acquired exclusive global rights to Quinsair, a proprietary, inhaled treatment for chronic pulmonary infections in adults with cystic fibrosis, in a deal with Triplex Pharmaceuticals. Notes Raptor President and CEO Julie Ann Smith, “”The Quinsair acquisition is transformational for Raptor and delivers on our strategic focus to develop and commercialize therapies that bring significant relief to patients and families living with life-threatening diseases. This acquisition expands our portfolio and leverages both our commercial and development expertise in rare diseases. By acquiring Quinsair prior to its launch, we will be able to exclusively shape its commercial strategy and potential in cystic fibrosis and other rare diseases.”
For more information on the acquisition, visit the Raptor Pharmaceutical website.